ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C14H10Cl2NNaO2
CAS番号:
分子量:
318.13
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C14H11Cl2NO2.Na/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1
SMILES string
[Na+].[O-]C(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl
InChI key
KPHWPUGNDIVLNH-UHFFFAOYSA-M
grade
pharmaceutical primary standard
API family
diclofenac
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... PTGS1(5742), PTGS2(5743)
類似した製品をお探しですか？ 訪問 製品比較ガイド
Biochem/physiol Actions
標準的なNSAIDかつシクロオキシゲナ-ゼ (COX) 阻害剤です。主要代謝産物は4´-ヒドロキシジクロフェナクおよび5´-ヒドロキシジクロフェナクです。CYP2C9に特異的な基質として用いられてきました。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Diclofenac sodium USP reference standard suitable for use in specified USP compendial quality tests and assays.
Also used to prepare acid stage standard, standard, standard stock, sensitivity, and system suitability solution for the assay, impurity analysis, identification, and performance test by using liquid chromatography coupled with UV detector according to the given below monographs of United States Pharmacopeia (USP):
Also used to prepare acid stage standard, standard, standard stock, sensitivity, and system suitability solution for the assay, impurity analysis, identification, and performance test by using liquid chromatography coupled with UV detector according to the given below monographs of United States Pharmacopeia (USP):
- Diclofenac Sodium
- Diclofenac Sodium Delayed-Release Tablets
- Diclofenac Sodium Extended-Release Tablets
- Diclofenac Sodium Topical Solution
- Diclofenac Sodium and Misoprostol Delayed-Release Tablets
General description
Diclofenac sodium is a sodium salt of diclofenac, a non-steroidal anti-inflammatory drug (NSAID). It prevents the synthesis of prostaglandin involved in pain, inflammation, and fever by inhibiting the cyclooxygenase enzyme activity.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Aquatic Chronic 2 - Repr. 2 - STOT RE 1
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
1188800-200MG:
jan
Adaptation of a color reaction for spectrophotometric determination of diclofenac sodium and piroxicam in pure form and in pharmaceutical formulations
El-Didamony, AM and Amin, AS
Analytical Letters, 37(6), 1151-1162 (2004)
R N Brogden et al.
Drugs, 20(1), 24-48 (1980-07-01)
Diclofenac sodium, a phenylacetic acid derivative, is a non-steroidal, anti-inflammatory, analgesic agent advocated for use in rheumatoid arthritis, degenerative joint disease, ankylosing spondylitis and allied conditions, and in the treatment of pain resulting from minor surgery, trauma and dysmenorrhoea. Published
D Aygün et al.
Histology and histopathology, 27(4), 417-436 (2012-03-01)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the purpose of anti-inflammation, antipyretic, and analgesia. For this aim, they are used for the alleviation of pain, fever, and inflammation associated with rheumatoid arthritis, sports injuries, and temporary pain. However, treatment
Paul L McCormack et al.
Drugs, 68(1), 123-130 (2007-12-18)
*A new formulation of the nonselective NSAID diclofenac sodium suitable for intravenous bolus injection has been developed using hydroxypropyl beta-cyclodextrin as a solubility enhancer (HPbetaCD diclofenac). * HPbetaCD diclofenac intravenous bolus injection was shown to be bioequivalent to the existing
R E Small
Clinical pharmacy, 8(8), 545-558 (1989-08-01)
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of diclofenac sodium are reviewed. Diclofenac, the first nonsteroidal anti-inflammatory agent (NSAID) to be approved that is a phenylacetic acid derivative, competes with arachidonic acid for binding to cyclo-oxygenase, resulting in
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）